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Acute myeloid leukemias (AMLs) with a rearrangement of the mixed-linage leukemia (MLL) gene are aggressive
hematopoietic malignancies. Here, we explored the feasibility of using the H3K9- and H3K36-specific demethylases
Jmjd2/Kdm4 as putative drug targets in MLL-AF9 translocated leukemia. Using Jmjd2a, Jmjd2b, and Jmjd2c con-
ditional triple-knockout mice,we show that Jmjd2/Kdm4 activities are required for MLL-AF9 translocated AML in
vivo and in vitro.We demonstrate that expression of the interleukin 3 receptor α (Il3ra also known as Cd123) subunit
is dependent on Jmjd2/Kdm4 through a mechanism involving removal of H3K9me3 from the promoter of the Il3ra
gene. Importantly, ectopic expression of Il3ra in Jmjd2/Kdm4 knockout cells alleviates the requirement of Jmjd2/
Kdm4 for the survival of AML cells, showing that Il3ra is a critical downstream target of Jmjd2/Kdm4 in leukemia.
These results suggest that the JMJD2/KDM4 proteins are promising drug targets for the treatment of AML.
[Keywords: acute myeloid leukemia; histone demethylase; H3K9 methylation; JMJD2; epigenetics; interleukin 3]
Supplemental material is available for this article.
Received March 6, 2016; revised version accepted May 4, 2016.
Acute myeloid leukemias (AMLs) with translocations
of the mixed-linage leukemia 1 (MLL1) gene are aggres-
sive hematopoietic malignancies. MLL1 translocations
occur in ∼35%–50% of infant AML cases and are fre-
quently found in therapy-related leukemia. Often, MLL1
translocated AML becomes refractory to chemotherapy,
and patients have a poor survival compared with patients
without MLL1 rearrangements using current treatment
protocols. Thus, there is an urgent need for the develop-
ment of novel therapies (Muntean and Hess 2012; de
Boer et al. 2013).
Mechanistic insight into the underlying molecular
basis of leukemogenesis driven by MLL1 fusions has ex-
panded significantly within recent years (Cai et al. 2015;
Chen and Armstrong 2015). Wild-type MLL1 is a histone
methyltransferasewith specificity toward H3K4 and is re-
quired for the transcription of 1.8% of mammalian genes,
including members of the homeobox (HOX) gene cluster
(Rao and Dou 2015). H3K4 methyltransferase activity is
lost in MLL1 fusions, and the mechanism of leukemogen-
esis is dependent on the fusion partner, most commonly
AF4, AF9, and ENL. The current hypothesis is that chime-
ric MLL1 fusion proteins maintain a leukemia-specific
gene expression pattern that is important for the survival
of AML cells (Bernt et al. 2011).
Several chromatin-associated enzymes have been found
to be required for the growth ofMLL-rearranged leukemia,
and small molecule inhibitors of some of these enzymes
are promising candidates for the development of new
drugs (Cai et al. 2015; Chen and Armstrong 2015). The
JMJD2 (also known as KDM4) enzymes are histone de-
methylases with specificity toward H3K9me3/me2 and
H3K36me3/me2 (Cloos et al. 2006; Fodor et al. 2006;Klose
et al. 2006; Whetstine et al. 2006). While H3K9me3 is
associatedwith transcriptional repression, when localized
on transcription start sites (TSSs), H3K36me3 is covering
actively transcribed regions of chromatin (Kouzarides
2007). The JMJD2/KDM4 protein family consists of
four members: JMJD2A, JMJD2B, JMJD2C, and JMJD2D.
While the JMJD2A, JMJD2B, and JMJD2C proteins are
highly homologous and expressed in most cell types,
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JMJD2D lacks the C-terminal part of the protein and
is mainly expressed in testis (Iwamori et al. 2011). The
JMJD2/KDM4 enzymes are overexpressed in multiple hu-
man cancers, and some studies have shown that they can
contribute to tumor cell proliferation (Cloos et al. 2006;
Kawazu et al. 2011; Shi et al. 2011; Luo et al. 2012). These
observations, in combination with a well-defined cata-
lytic mechanism, define these enzymes as attractive
drug targets (Kooistra and Helin 2012; Berry and Jan-
knecht 2013; Hojfeldt et al. 2013).
In this study, we used mice in which Jmjd2a, Jmjd2b,
and Jmjd2c are conditionally deleted to probe the thera-
peutic potential of targeting Jmjd2/Kdm4 activity in a
mouse model of MLL-AF9-driven leukemia.
Results
Jmjd2a, Jmjd2b, and Jmjd2c are required for progression
of MLL-AF9 translocated leukemia in vivo
Retroviral-mediated expression of MLL-AF9 can trans-
form general myeloid progenitors (GMPs) into immortal-
ized leukemic blast cells in vitro, and mice transplanted
with these cells develop AML (Krivtsov et al. 2006;
Somervaille and Cleary 2006). Using this system in com-
bination with knockout mouse strains that we generated
(Pedersen et al. 2016), we developed a mouse model
of MLL-AF9 translocated AML that is conditionally
knocked out for Jmjd2/Kdm4 activity. In cells from these
mice, loxP sites are flanking critical exons in Jmjd2a,
Jmjd2b, and Jmjd2c, and, in addition, an inducible form of
Cre recombinase (CreERT2) is expressed from the Rosa26
locus (we refer to this mouse strain as 2abc;CreER). The
activity of CreERT2 can be activated by 4-hydroxytamox-
ifen (OHT) in vitro and in vivo.
We isolated c-Kit+ cells from the bone marrow (BM)
of Jmjd2c;CreER and Jmjd2abc;CreER mice. The cells
were transduced with a retrovirus expressing MLL-AF9,
plated in methocult medium, and subsequently serially
replated three times to enrich for preleukemic GMPs
(denoted as pre-MA9-2c and pre-MA9-2abc) (Fig. 1A).
To investigate the role of Jmjd2/Kdm4 in MLL-AF9-in-
duced transformation of GMPs, we examined the cell
growth and colony-forming capability of preleukemic
GMPs.AdditionofOHTto the growthmediumresulted in
efficient depletion of Jmd2a, Jmjd2b, and Jmjd2c in pre-
MA9-2abc and Jmjd2c in pre-MA9-2c cells (Supplemental
Fig. 1A). Strikingly, the deletion of Jmjd2a, Jmjd2b, and
Jmjd2c, but not Jmjd2c alone, led to a strong attenuation
of growth in liquid culture (Supplemental Fig. 1B).
Having established that the combined activity of
Jmjd2a, Jmjd2b, and Jmjd2c is required for the growth of
preleukemic GMPs, we tested whether these proteins
also are required for MLL-AF9 translocated leukemia in
vivo. We transplanted pre-MA9-2abc and pre-MA9-2c
cells into sublethally irradiated recipient mice (Fig. 1A).
At day 21 after transplantation, the mice were injected
with tamoxifen (converted to OHT in the mouse liver)
daily over a period of 10 consecutive days to induce knock-
out of Jmjd2a, Jmjd2b, and Jmjd2c. While deletion of
Jmjd2c alone did not have any significant effect on mouse
(leukemic) survival (Fig. 1B), the combined deletion of
Jmjd2a, Jmjd2b, and Jmjd2c resulted in a substantial ex-
tension of life span of the mice (P = 0.0009) (Fig. 1C). In
these experiments, FACS analyses of spleen cells from
leukemic mice were performed to confirm the emergence
of AML; i.e., infiltration of Gr1+/Mac1+-positive cells in
the spleen (Fig. 1D). Two tamoxifen-treated MA9-2abc
mice became leukemic (Fig. 1C), but, notably, genotyping
showed that the leukemic cells from one of these mice
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Figure 1. MLL-AF9 cells are dependent on the com-
bined activity of Jmjd2a, Jmjd2c, and Jmjd2c in vivo.
(A) Schematic drawing of the experimental setup.
(B,C ) Kaplan-Meier curve depicting the survival of
mice transplanted with 5 × 104 preleukemic cells
with the indicated genotypes. Twenty-one days after
transplantation, the mice were injected daily with
1 mg of tamoxifen dissolved in oil or with oil alone
for a period of 10 d (indicated as a gray area in the
growth curve). The median survival of MA9-2abc
mice injected with oil was 112.5 d; for MA9-2abc
mice injected with tamoxifen, the median survival
was not reached; for MA9-2c mice injected with oil,
the median survival was 99.5 d; and for MA9-2c
mice injected with tamoxifen, the median survival
was 93 d. P-values are the result of aMantel-Cox stat-
istical test. (D) Representative FACS plots of cells
from the spleen of a leukemic mouse. Plots show
Gr1+ and Mac1+ double-positive in the CD45.2 gate.
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had retained the wild-type alleles and therefore represent-
ed an escaper clone (data not shown).
To investigate the effect of deleting Jmjd2a, Jmjd2b,
and Jmjd2c on normal hematopoietic development,we re-
constituted the hematopoietic system in lethally irradi-
ated mice using untransformed BM cells from 2abc;
CreERmice or wild-type controls. Injection of tamoxifen
into these mice resulted in efficient recombination of the
floxed alleles of Jmjd2a, Jmjd2b, and Jmjd2c in CD45.2-
positive donor cells, as evident upon FACS sorting of pe-
ripheral blood (Supplemental Fig. 2A). However, we did
not observe any significant changes in overall CD45.2
chimerism or survival of the mice within a 3-mo period
(Supplemental Fig. 2B,C). These results demonstrate that
hematopoiesis can develop to some extent in the absence
of Jmjd2a, Jmjd2b, and Jmjd2c.
Taken together, we conclude that the simultaneous
knockout of Jmjd2a, Jmjd2b, and Jmjd2c perturbs the
progression of MLL-AF9 translocated leukemia in mice,
whereas inactivation of Jmjd2c alone does not have any
effect. Likewise, we found that knockout of Jmjd2a,
Jmjd2b, and Jmjd2c does not result in any severe pheno-
type in untransformed BM cells and that Jmjd2abc;CreER
donor cells can contribute sufficiently to the hematopoi-
etic system to make recipients survive.
Loss of Jmjd2/Kdm4 compromises the proliferative
capacity of MLL-AF9 transformed GMPs (L-GMPs)
Having established that Jmjd2/Kdm4 is required for AML
in vivo, wewanted to understand how loss of Jmjd2/Kdm4
affects the growth of L-GMPs. To do this, we examined
the growth and colony formation capability of leukemic
cells isolated from the BM of moribund pre-MA9-2c and
pre-MA9-2abc transplanted mice that had been injected
with oil. In these cells, Jmjd2a, Jmjd2b, and Jmjd2c are
still wild type, and genetic inactivation of the Jmjd2/
Kdm4 genes can be induced in vitro. Treatment of these
cells in liquid culture for 96 h with 500 nM OHT resulted
in an efficient depletion of Jmjd2a, Jmjd2b, and Jmjd2c
protein and mRNA (Fig. 2A,B).
We found that proliferation of two independently iso-
lated leukemic MA9-2abc cell lines (L-MA9-2abc-1 and
L-MA9-2abc-2) in liquid culture was severely compro-
mised upon OHT treatment, whereas the proliferation of
L-MA9-2c cells was unaffected (Fig. 2C). Similarly, the
ability to form colonies in methylcellulose was lower for
L-MA9-2abc cells treated with OHT compared with un-
treated cells, whereas no effect of OHT treatment was ob-
served for L-MA9-2c cells (Fig. 2D). Deletion of Jmjd2a,
Jmjd2b, and Jmjd2c resulted in increased levels of cell
death, elevated levels of Mac1, and slightly reduced num-
bers of S-phase cells (Fig. 2E–G) as well as an increased
number of differentiated cells (Fig. 2H). In contrast, we ob-
served only a modest effect on growth of untransformed
c-Kit-positive BM cells upon knockout of Jmjd2a, Jmjd2b,
and Jmjd2c (Fig. 2I), which is in agreement with our in
vivo observations (Supplemental Fig. 2A–C).
In summary, these data suggest that the extended life
spanof leukemicmiceafter genetic inactivationof Jmjd2a,
Jmjd2b, and Jmjd2c is the result of enhanced levels of dif-
ferentiation and cell death of the leukemic cells.
Jmjd2/Kdm4 proteins are required for the survival of
MLL-AF9 transformed cells independently of Hoxa9
and Meis1
MLL-AF9 directly regulates the transcription of Hoxa9
and Meis1, which are essential downstream targets for
MLL-AF9 during leukemic transformation. This is under-
scored by the fact that coexpression of Hoxa9 andMeis1 is
sufficient to induce transformation of GMPs (Kroon et al.
1998; Wang et al. 2010). In a recent study published while
this work was in preparation, it was reported that Jmjd2c
binds to MLL-AF9 and is an essential cofactor for the
transcriptional activation ofHoxa9 andMeis1 during leu-
kemic transformation (Cheung et al. 2016). According
to this study, Jmjd2c is recruited to the TSSs of Hoxa9
and Meis1, where it can demethylate H3K9me3 (Cheung
et al. 2016). Additionally, it was reported that Jmjd2c
alone is required for leukemic transformation by MLL-
AF9 (Cheung et al. 2016), a conclusion that contrasts with
our data showing that deletion of Jmjd2c alone has no ef-
fect on leukemic transformation, while only the simulta-
neous deletion of Jmjd2a, Jmjd2b, and Jmjd2c results in
attenuation of leukemic growth. To understand whether
transcription of Hoxa9 and Meis1 was affected upon ge-
netic inactivation of Jmjd2a, Jmjd2b, and Jmjd2c, we per-
formed RT-qPCR analysis on L-MA9-2c and L-MA9-2abc
cells. However, we did not observe any significant effect
on Hoxa9 and Meis1 mRNA levels upon OHT-induced
deletion of Jmjd2c alone or from the simultaneous dele-
tion of Jmjd2a, Jmjd2b, and Jmjd2c (Fig. 3A).
To further address whether Hoxa9 and Meis1 could
have a role in the observed growth defect, we took advan-
tage of the fact that GMPs can be transformed by the
coexpression of Hoxa9 andMeis1 (Kroon et al. 1998). We
speculated that if Jmjd2/Kdm4, similar to Dot1L (Bernt
and Armstrong 2011), is genetically upstream of Hoxa9
andMeis1, then cells transformed with Hoxa9 andMeis1
would be unresponsive to knockout of Jmjd2/Kdm4. On
the other hand, if the growth defect is still observed in
Hoxa9–Meis1 transformed cells, then the Jmjd2/Kdm4
proteins are required downstream from Hoxa9 and Meis1
or in a parallel independent pathway. We purified c-Kit+
cells from the BM of Jmjd2c;CreER and Jmjd2abc;CreER
mice and transduced them with retroviruses coexpress-
ing Hoxa9 and Meis1. After three rounds of replating
in methylcellulose, the cells were transferred to liquid
medium and treated with 500 nM OHT for 96 h. As ob-
served in MLL-AF9 transformed cells, OHT treatment re-
sulted in efficient knockout of Jmjd2a, Jmjd2b, and
Jmjd2c (Fig. 3B). This led to an even stronger effect on
growth than that observed inMLL-AF9 transformed cells,
whereas knockout of Jmjd2c alone did not have any effect
(Fig. 3C).
From these data, we conclude that Jmjd2a, Jmjd2b, and
Jmjd2c are required for maintaining the transformed phe-
notype of MLL-AF9 leukemia downstream from Hoxa9
andMeis1 or in a parallel independent pathway.
Agger et al.
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Jmjd2a and Jmjd2c bind to H3K4me3-positive TSSs in
MLL-AF9 transformed cells
Having established that the requirement of the Jmjd2/
Kdm4 proteins for the survival of MLL-AF9 transformed
AML cells cannot be explained by the lack of Hoxa9 and
Meis1 expression, we performed unbiased genome-wide
studies (i.e., genome-wide location analysis in combina-
tion with expression studies). We mapped the binding
patterns of Jmjd2a and Jmjd2c in L-MA9-2abc cells by
chromatin immunoprecipitation (ChIP) combined with
high-throughput sequencing (ChIP-seq). Due to the lack
of ChIP-grade antibodies, a similar analysis was not per-
formed for Jmjd2b (data not shown). Using OHT-treated
L-MA9-2abc cells devoid of Jmjd2 proteins as a negative
control, bioinformatics analysis identified 8977 signifi-
cantly bound regions representative of Jmjd2a-binding
sites, of which 77% were localized within ±1 kb of an
annotated TSS. For Jmjd2c, we identified 10,521 signi-
ficantly bound regions, of which 86% localized within
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±1 kb of a TSS (Fig. 4A). The binding of Jmjd2a and Jmjd2c
was confirmed in an independent biological experiment
by ChIP-qPCR on a selected target (Fig. 4B). Although
the phenotype that we observed upon Jmjd2/Kdm4 deple-
tion was not dependent on deregulated Hoxa9 andMeis1
transcription, Jmjd2cwas found to bind to the promoter of
Meis1 andHoxa9, in agreement with Cheung et al. (2016)
(Supplemental Fig. 3A,B).
Previously, we reported that Jmjd2a and Jmjd2c both
localize to H3K4me3-positive TSSs in mouse embryonic
stem cells (mESCs) (Pedersen et al. 2014, 2016). Similar
to what was observed for Jmjd2a and Jmjd2c in mESCs,
we found a strong overlap in Jmjd2a- and Jmjd2c-binding
patterns (Fig. 4C,D; Supplemental Fig. 4A,B) and observed
that the vast majority of Jmjd2a- and Jmjd2c-binding
sites overlap H3K4me3-marked regions (Fig. 4D; Supple-
mental Fig. 4C,D). In this way, we found that 94% and
97% of TSS-associated Jmjd2a and Jmjd2c peaks directly
overlap an H3K4me3 peak (Supplemental Fig. 4C,D) and
that 6940 TSS regions are bound by both Jmjd2a and
Jmjd2c in L-MA9-2abc cells (Fig. 4C). This is in agree-
ment with a model in which Jmjd2a and Jmjd2c exert re-
dundant functions at H3K4me3-marked TSSs in L-MA9-
2abc cells.
The Jmjd2/Kdm4 enzymes catalyze demethylation of
Lys9 and Lys36 on histone H3. To identify regions that
change H3K9me3 and H3K36me3 levels after genetic in-
activation of Jmjd2a, Jmjd2b, and Jmjd2c, we performed
ChIP-seq experiments. Here, we used antibodies specifi-
cally recognizing H3K9me3 and H3K36me3 as well as
chromatin from control L-MA9-2abc cells or L-MA9-
2abc cells that had been treated with OHT for 96 h. The
heat maps (Fig. 4E; Supplemental Fig. 5A) present two
biologically independent experiments and depict the
H3K9me3 and H3K36me3 reads around the 6940 TSSs
cobound by Jmjd2a and Jmjd2c in L-MA9-2abc cells cul-
tured in the absence or presence of OHT. It is evident
that the H3K9me3 levels are strongly increased by the
simultaneous deletion of Jmjd2a, Jmjd2b, and Jmjd2c on
a subset of the cobound TSSs (Fig. 4E, top part of the
heat map). Increased H3K9me3 levels were confirmed by
ChIP-qPCR on selected Jmjd2a and Jmjd2c target genes
(Fig. 4B). For H3K36me3, we also observed an increase in
methylation levels, shifting the profiles toward the TSS
at Jmjd2a/Jmjd2c-cobound regions upon Jmjd2/Kdm4
depletion (Supplemental Fig. 5A).
Taken together, we demonstrated that Jmjd2a and
Jmjd2c both localize to H3K4me3-positive TSSs in MLL-
AF9 transformed leukemic cells, where they prevent ac-
cumulation of H3K9me3 and H3K36me3.
Jmjd2-mediated H3K9me3 demethylation is required
for the expression of interleukin 3 receptor α (Il3ra)
We hypothesized that Jmjd2/Kdm4 proteins are required
for the transcription of a gene or group of genes in
L-MA9-2abc cells and that loss of expression of some of
these genes could explain the observed growth defect.
To identify such genes, we performed gene expression
analysis on three independently derived L-MA9-2abc cell
lines cultured in the absence or presence of OHT for 96
h. When setting the cutoff at an absolute fold change of
>2with a false discovery rate (FDR) of <0.05, we found that
the combined loss of Jmjd2a, Jmjd2b, and Jmjd2c led to
down-regulation of 94 genes and up-regulation of 55 genes
(Fig. 5A). Thirty of the down-regulated genes (32%) and 11
of the up-regulated genes (20%) contained binding sites
for both Jmjd2a and Jmd2c within ±1 kb of a TSS (Fig.
5B). Gene set enrichment analysis (GSEA) of the array
data did not reveal any enrichment ofHoxA9/Meis1 target
genes, indicating that Jmjd2/Kdm4 proteins are not func-
tioning directly downstream fromHoxA9/Meis1 but rath-
er in a parallel independent pathway (data not shown).
Loss of Jmjd2/Kdm4 can result in both direct and indi-
rect effects on transcription; however, the direct targets
of Jmjd2/Kdm4 are expected to have increased levels of
H3K9me3 or H3K36me3 at their TSSs upon depletion of
Jmjd2 proteins. In order to link transcription and histone
methylation, we analyzed H3K9me3 and H3K36me3
levels at TSSs of deregulated genes. Similar to our observa-
tions inmESCs, we found a correlation between increased
H3K9me3 levels and transcriptional repression of Jmjd2a/
c targets, whereas the data did not reveal a link be-
tween Jmjd2/Kdm4-dependent control of H3K36me3
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Figure 3. Jmjd2/Kdm4 proteins are required for the survival of
MLL-AF9 transformed cells downstream from Hoxa9 and
Meis1. (A) RT-qPCR of Hoxa9 and Meis1 using mRNA prepared
from two independently derived L-MA9-2abc cell lines and one
L-MA9-2c cell line treated with or without 500 nM OHT for
96 h. (B) Depletion efficiency of Jmjd2a, Jmjd2b, and Jmjd2c
measured by RT-qPCR in HoxA9–Meis1 (HM) transformed pre-
leukemic cells after 96 h of treatment with 500 nM OHT.
(C ) Growth curve of the same cells as in B in liquid culture.
The growth curve was started after 96 h of OHT treatment. The
graphs showmean ± SDof technical replicates and are representa-
tive of at least three independent experiments.
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and transcriptional changes (Supplemental Fig. 5B,C; Pe-
dersen et al. 2016).
Among the 30 down-regulated genes cobound by Jmjd2a
and Jmjd2c, we identified five genes that showed a more
than twofold increase in H3K9me3 levels upon loss of
Jmjd2/Kdm4 expression in both ChIP-seq experiments
(Fig. 5A). Among these five genes, we reasoned that Il3ra
(also known asCd123) could be a strong candidate for me-
diating the phenotype. Il3ra is the α subunit of the hetero-
dimeric Il-3 receptor that, together with the β subunit (Il3
receptor β), forms a functional high-affinity receptor. Bind-
ing of Il-3 to the receptor results in activation of receptor-
associated Janus kinases (JAKs) and its downstream STAT
pathway, which ultimately leads to stimulation of prolif-
eration. A considerable number of results have indicated
that IL-3 and its receptor play important roles in the
survival of AML as well as in inflammation (Broughton
et al. 2012; Testa et al. 2014).
We validated the transcriptional down-regulation of
Il3ra by RT-qPCR in two different L-MA9-2abc cell lines
(Fig. 5C). In contrast, we observed only aminor decrease in
expression of Il3ra upon OHT treatment of the L-MA9-2c
control cell line (Fig. 5C). Moreover, we confirmed that
Jmjd2a and Jmjd2c colocalize with H3K4me3 at the TSS
of Il3ra and that genetic deletion of Jmjd2a, Jmjd2b,
and Jmjd2c led to an increase in H3K9me3 levels at the
TSS (Figs. 4B, 5D). These data strongly suggest that the
Jmjd2/Kdm4 proteins are required for the expression of
Il3ra through a process involving the specific demethyla-
tion of H3K9 at the TSS of the gene. In agreement with
this, GSEA revealed impaired expression of genes down-
stream from Il3ra in cells depleted for Jmjd2a, Jmjd2b,
and Jmjd2c (Fig. 5E; Supplemental Fig. 3E).
To investigate whether Il3ra is a critical downstream
target of the Jmjd2/Kdm4 proteins in L-MA9-2abc cells,
we performed a genetic rescue experiment. We cloned
Figure 4. ChIP-seq analyses of Jmjd2a, Jmjd2c, and
H3K9me3 in MA9-2abc. (A) Pie diagrams showing the
distribution of Jmjd2a- and Jmjd2c-binding sites rela-
tive to annotated TSSs and transcription end sites
(TESs) in L-MA9-2abc cells. (B) Independent ChIP-
qPCR validation of ChIP-seq data on a selected TSS
cobound by Jmjd2a and Jmjd2c, showing increased
H3K9me3 levels after OHT treatment. (C ) Venn dia-
gram showing the number of TSSs containing binding
sites for Jmjd2a and/or Jmjd2c within ±1 kb. The P-val-
ue was calculated using a hypergeometric test. (D) Un-
supervised k-means clustering of ChIP-seq tags over all
TSSs (±5 kb). H3K4me3 ChIP-seq data were from Bernt
et al. (2011). (E) H3K9me3 ChIP-seq tags over Jmjd2a/c
cobound TSSs ± 5 kb as defined in C, ranked by read
counts in the +OHT condition. The graphs showmean
± SD of technical replicates and are representative of at
least three independent experiments.
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the ORF of the murine Il3ra cDNA into a retroviral ex-
pression vector containing a selectable marker (MSCV-
Il3ra) and transduced L-MA9-2abc cells with this con-
struct. As shown in Figure 5F, ectopic expression of Il3ra
in L-MA9-2abc cells resulted in a rescue of the growth
defect observed upon Jmjd2/Kdm4 depletion by OHT
treatment.
In conclusion, we found that Jmjd2/Kdm4 proteins are
required for the leukemic growth of AMLs driven by the
MLL-AF9 fusion protein. Specifically, the Jmjd2/Kdm4
proteins are required for the expression of Il3ra, and ectop-
ic expression of Il3ra alleviates the requirement for Jmjd2/
Kdm4 proteins in MLL-AF9 translocated AMLs.
Discussion
The results presented here demonstrate that targeting of
Jmjd2/Kdm4 activity in MLL-AF9 translocated AML is a
feasible strategy for the development of novel therapies.
We show that depletion of Jmjd2/Kdm4 activity through
the simultaneous genetic inactivation of Jmjd2a, Jmjd2b,
and Jmjd2c is deleterious to the survival of leukemic cells
in a mouse model of MLL-AF9 translocated AML, where-
as depletion of Jmjd2c alone does not have any effect,
indicating redundant roles of Jmjd2a, Jmjd2b, and Jmjd2c
in AML. We also show that Jmjd2/Kdm4 depletion in
nontransformed c-Kit+ BM cells in vitro as well as in
vivo has a less pronounced effect on cellular growth, open-
ing a therapeutic window of opportunity for the targeting
of Jmjd2/Kdm4 activity in AML.
A report published while this study was in preparation
suggests an essential role for Jmjd2c alone in the survival
MLL-AF9 translocated AML (Cheung et al. 2016). Howev-
er, our results differ from the published observations in
two conceptually important ways. First, we did not see
any effect on the survival of MLL-AF9 translocated AML
upon deletion of Jmjd2c alone either in vivo or in vitro.
Second, our data do not support a model in which Jmjd2c
Figure 5. Jmjd2/Kdm4 activity is required for the expression of Il3ra inMA9-2abc cells. (A) Heat map representing gene expression anal-
ysis of L-MA9-2abc cells after 96 h of treatment with 500 nMOHT. Data are presented for genes with deregulated expression (fold change
>2; FDR <0.05), genes cobound by Jmjd2a and Jmjd2c and displaying amore than twofold increase inH3K9me3 levels are indicated. (B) Bar
diagram showing the number of deregulated genes (fold change >2; FDR<0.05) containing binding sites for Jmjd2a and/or Jmjd2cwithin ±1
kb of a TSS. (C ) RT-qPCR validation of transcriptional repression of Il3ra in two independently derived L-MA9-2abc cell lines and one
L-MA9-2c cell line. (D) H3K4me3 (Bernt et al. 2011), Jmjd2a, Jmjd2c, and H3K9me3 ChIP-seq tracks of the Il3ra locus with and without
combined depletion of Jmjd2a, Jmjd2b, and Jmjd2c. The area around the TSS is indicated by two vertical lines. (E) GSEA plot showing im-
paired expression of a gene set induced by IL-3 treatment in human AML samples (Sadras et al. 2014) in OHT-treated L-MA9-2abc cells.
(NES) Normalized enrichment score; (p) nominal P-value. (F ) Growth curve of MA9-2abc cells transduced with MSCV-Il3ra or empty
MSCV vector. Cells were grown in the absence or presence of 500 nMOHT in liquid culture. Data are presented asmean ± SD of technical
replicates and are representative of at least three independent experiments.
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is required for the regulation of Hoxa9 and Meis1 tran-
scription. Although these differences can be hard to recon-
cile, the first discrepancy could be due to the fact that
experiments presented by Cheung et al. (2016) mainly re-
lied on the usage of shRNA, which can have substantial
off-target effects. In contrast, in our studies, we used a ge-
netic knockout model that is not associated with off-
target effects. We did not test whether the Jmjd2/Kdm4
proteins can bind to MLL-AF9; however, our results do
not support amodel inwhichHoxa9 andMeis1 are critical
targets for the Jmjd2/Kdm4 proteins in AML because we
did not observe amajor effect onHoxa9 andMeis1 expres-
sion in the absence of the Jmjd2/Kdm4 proteins. More-
over, our genetic studies show that the Jmjd2/Kdm4
proteins are required downstream from Hoxa9 and Meis1
or in a parallel independent pathway.
To identify the direct targets for Jmd2/Kdm4 that could
explain the requirements for these proteins in MLL-AF9
translocated AMLs, we mapped the genomic binding
sites for Jmjd2a and Jmjd2c in mouse leukemic cells. Us-
ing our triple-knockout cells, we identified functionally
important binding sites where loss of Jmjd2/Kdm4 was
coincidental with increased H3K9me3 levels. The combi-
nation of genome-widemapping analysis and gene expres-
sion analysis enabled us to pinpoint Il3ra as an essential
transcriptional target of Jmjd2/Kdm4 proteins in AML.
Il3ra (Cd123) is a nonessential gene inmice (Nishinaka-
mura et al. 1995). It has previously been found over-
expressed in several types of leukemia, such as AML,
B-progenitor acute lymphoblastic leukemia (B-ALL),
T-cell ALL (T-ALL), and chronic lymphocytic leukemia
(CLL), and targeting IL3RA-expressing cells using neutral-
izing antibodies against IL3RA as well as IL3RA antibod-
ies coupled to toxins has shown beneficial effects on
survival in AML models (Jordan et al. 2000; Testa et al.
2002; Jin et al. 2009; Liu et al. 2015). Notably, two phase
I clinical trials using IL3RA monoclonal antibodies for
the treatment of AML are currently being completed
(http://www.clinicaltrials.gov); the results from these
trials have not been published yet, and the outcomes are
therefore uncertain. Our results provide an exciting possi-
bility by showing that inhibiting Jmjd2/Kdm4 activity
could be a feasible alternative treatment strategy for leu-
kemia with high expression of IL3RA.
Binding of Il-3 to the receptor results in activation of
receptor-associated JAKs and its downstream STAT path-
way, which promotes both cell proliferation and survival.
Although MLL rearrangements alone are sufficient to
drive some forms of childhood leukemia, activatingmuta-
tions downstream from Il3ra in, for instance, FLT3 and N-
RAS are often observed in combination with MLL rear-
rangements (Andersson et al. 2015). There is a possibility
that mutations in FLT3 and NRAS could relieve the re-
quirement for Jmjd2/Kdm4 during leukemic transforma-
tion, and it is important to address this in future studies.
Cheung et al. (2016) recently published the use of a
chemical compound, SD70, to inhibit AML growth in
vivo. Although the target specificity of SD70 is not
known, the demonstration that it can inhibit the deme-
thylation activity of JMJD2C/KDM4C in vitro (although
with a low IC50 of ∼30 µM) (Jin et al. 2014) could be
used as an argument to propose that this study provided
some proof of concept for targeting the JMJD2/KDM4
demethylases in AML. In recent years, several mechanis-
tic-based inhibitors toward the catalytic JmjC domain of
the histone demethylases have been studied; however,
so far, none of these have been shown to be selective
for the JMJD2/KDM4 demethylases (Wang et al. 2013;
Bavetsias et al. 2016; Westaway et al. 2016a,b). Because
the JmjC demethylases can function as both tumor sup-
pressors and oncogenes, it will be essential to develop sub-
family-specific chemical inhibitors for therapeutic use.
Based on the studies presented here, we hope that the
available inhibitors will be refined so that, in a few years,
we can test the feasibility of using JMJD2/KDM4-specific
inhibitors for the treatment of AML.
Material and methods
Mice
Generation of Jmjd2a/b/cf/f;Rosa26::CreERT2 mice is de-
scribed in Pedersen et al. (2016). B6.SJL mice were used as
recipients in the transplantation experiments. Trans-
planted mice were inspected daily, and moribund mice
were euthanized by cervical translocation. The emer-
gence of AML was confirmed by the presence of Gr1/
Mac1-double-positive CD45.2 cells in the spleen. One
representative FACS plot is shown in Figure 1D. All
mouse work was approved by the Danish Animal Ethical
Committee (“Dyreforsøgstilsynet”) under license number
2012-15-2934-00224.
BM transplantation
c-Kit+ BM cells from Jmjd2a/b/cf/f;Rosa26::CreERT2
and Jmjd2cf/f;Rosa26::CreERT2 mice were transduced
with MSCV-MLL-AF9-neo. After 2 d, cells were plated
in methylcellulose medium (Stem Cell Technologies,
M3532) containing 50 ng/mL SCF, 10 ng/mL IL-6, 10 ng/
mL IL-3, and neomycin. Following three rounds of re-
plating, 5 × 104 preleukemic cells were transplanted into
sublethally irradiated (600 rad) B6.SJL mice by tail vein
injections.
Virus production
Phoenix-Ecotropic cells were transfected withMSCV vec-
tors using the standard calcium phosphate transfection
method. Forty-eight hours after removal of transfection
mix, viral supernatants were harvested and centrifuged
on Retronectin-coated plates that were subsequently
used to transduce c-Kit+ cells. The Gateway Entryclone-
encoding murine Il3ra ORF was obtained fromGenopedia
and subcloned into MSCV using LR clonase.
In vitro culture of MLL-AF9 transformed cells
Liquid culture of MLL-AF9 and Hoxa9–Meis1 trans-
formed cells was done in RPMI containing 20% FBS and
10 ng/mL IL-3. Leukemic cell lines were derived by
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explanting cells from the BM of leukemicmice into RPMI
containing 20% FBS and 10 ng/mL IL-3.
EdU incorporation
EdU incorporation assay was performed according to
the manufacturer’s protocol using Click-It EdU assay
(Thermo Fisher).
RNA and gene expression analyses
RNA was purified using the RNeasy kit (Qiagen) and
reverse-transcribed using TaqMan reverse transcription
reagents (Applied Biosystems) according to the manufac-
turer’s instructions. In RT-qPCR experiments, expression
values were normalized to the housekeeping gene Rplp0.
All qPCR reactions were performed on a Roche LightCy-
cler 480 II using SYBR Green master mix. For microarray
analysis, RNA from three independently derived MA9-
2abc leukemic cell lines was isolated after 96 h of treat-
ment with 500 nMOHT or control. Samples were labeled
and hybridized to Agilent SurePrint G3 mouse GE 8x60K
arrays (Agilent, G4852A) according to the manufacturer’s
instructions using LowInput QuickAmp One-Color label-
ing kit (Agilent, 5190-2305), One-Color RNA Spike-In kit
(Agilent, 5188-5282), and gene expression hybridization
kit (Agilent, 5188-5242). Array probe annotation was
downloaded from the Agilent Web site and subsequently
converted to an R package using AnnotationForge. In R,
we performed background correction (“normexp,” offset
= 75), normalization (“cyclicloess”), filtering, and statisti-
cal analysis using the limma package. Test P-values were
converted to FDR values to adjust for multiple testing.
Antibodies
The specificity of H3K9me3 antibodies was tested in
ELISA experiments with a histone peptide library (Peder-
sen et al. 2014). Polyclonal antibodies against Jmjd2b
and Jmjd2c have been described previously (Pedersen
et al. 2014). The following commercially available anti-
bodies were used: anti-Jmjd2a (Cell Signaling Techno-
logy, 5328), anti-β actin (Abcam, ab6276), anti-H3K9me3
(Abcam, ab8898), anti-H3 (Abcam, ab1791), anti-mouse
CD11b (Biolegend, clone MI78), and anti-mouse Ly-6g/
Ly-6c (Biolegend, RB6-8C5).
Western blot analysis
Protein lysates andWestern blot analysis were done using
standard protocols.
GSEA
GSEA (Subramanian et al. 2005) was performed with
GSEA version 2.2.1 software obtained from the Broad
Institute Web site. The PID_IL3_PATHWAY gene set
was obtained from the Molecular Signature Database,
and the gene set induced by IL-3 treatment of human
AML samples (sustained response) was described in Sad-
ras et al. (2014).
ChIP and ChIP-seq
ChIP experiments were performed as described in Kleine-
Kohlbrecher et al. (2010), and ChIP-seq libraries were
made using NEBNext Ultra II DNA library preparation
kit for Illumina according to the manufacturer’s protocol.
Reads were mapped to the mouse genome (mm10 assem-
bly) using Bowtie for Illumina (Galaxy tool version 1.1.2)
(Langmead et al. 2009). Mapped reads were filtered for
PCR duplicates using RmDup (version 0.1.19). Peak call-
ing and visualization of tracks were done using EaSeq
(http://www.easeq.net) (Lerdrup et al. 2016), and heat
maps were made using seqMINER (Ye et al. 2011). ChIP-
seq tracks of H3K4me3 in mouse leukemia stem cells
were visualized using EaSeq with data from GSE29130
(Bernt et al. 2011). Chromosomal positions were annotat-
ed according to the RefSeq database (mm10; January 19,
2015) using the University of California at Santa Cruz
refFlat tables. In our annotation, a TSS region is defined
as ±1 kb relative to the TSS. For density plots, we generat-
ed bigwig files allowing only one read per chromosomal
position, eliminating potential spurious spikes. Each re-
maining readwas extended from its 5′ end to a total length
of 250 bases. Each bigwig file was also scaled to TPM (tags
permillion) based on the number of unique read positions.
For density plots, the regions of ±5 kb for all annotated
TSSs were divided into 100 equal-sized bins.
Primer sequences
For RT-qPCR, the primer sequences used were Jmjd2a_F
(AAGAAAGCCATGACCGTTCGTG), Jmjd2a_R(AAAT
TCACTGTATCGCGGGGTG), Jmjd2b_F (GATCATGA
CTTTCCGCCCCA), Jmjd2b_R (TCATCATACGTCTG
CCGTGG), Jmjd2c_F (GCCAGATAGATACCAGATTT
G), Jmjd2c_R (GGCAGGGTTTGCACCCTCTTC), Il3ra_F
(CTGTGAAGACAGCCTTGGTG), Il3ra_R (GCGGTAG
AGCAGCGACTTC), Rp0lp_F (TTCATTGTGGGAGCA-
GAC), and Rp0lp_R (CAGCAGTTTCTCCAGAGC).
For ChIP-qPCR, the primer sequences used were
Il3ra_TSS_F (ACTTGCCAGCATCCTCCA) and Il3ra_
TSS_R (AGTGCAGATGACAAGGCAGA).
Accession codes
ChIP-seq and microarray data have been deposited in the
Gene ExpressionOmnibus (GEO) databasewith accession
number GSE81300.
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